Work

Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Year: 2021

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2021.05.017

Authors: Andrzej Jakubowiak, Saad Z. Usmani, Amrita Krishnan, Sagar Lonial, Raymond L. Comenzo, Jianping Wang, Carla de Boer, William Deraedt, Brendan M. Weiss, Jordan M. Schecter, Ajai Chari

Institutions: University of Chicago Medical Center, Levine Cancer Institute, City Of Hope National Medical Center, City of Hope, Emory University, Winship Cancer Institute, Tufts Medical Center, Janssen Research & Development (United States), Janssen (Netherlands), Janssen (Belgium), Abramson Cancer Center, University of Pennsylvania, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Takeda Pharmaceuticals U.S.A., Janssen Research and Development, Janssen Pharmaceuticals

OpenAlex ID: W3171552343

FWCI: 0.969

Cites: 53

Cited by: 12

Related to: 10